Alpha 2.0
Login Register
» Articles » PMID: 808913

Control of Meningococcal Meningitis with Meningococcal Vaccines

Overview
Journal Yale J Biol Med
Specialty Biology
Date 1975 Jul 1
PMID 808913
Citations 6
Authors
M S Artenstein
Affiliations
Soon will be listed here.
Abstract

The development of effective meinigococcal vaccines was based upon the finding that immunity to the meningococcus was directly correlated with serum bactericidal antibodies. Purified high molecular weight capsular polysaccharides of serogroups A and C meningococci stimulated the production of humoral antibodies which had group specific bactericidal activity. In controlled field trials in Army recruits, group C polysaccharide vaccines were highly effective in preventing group C disease. Following its use as a routine immunization in recruits in October 1971 group C meningococcal disease has been almost completely eliminated from Army training centers. Group A vaccine has been field tested in Egyptian school children with great success. Group B polysaccharide has failed to induce bactericidal antibodies in humans and, therefore, new research is underway to attempt to develop a cell wall protein antigen as a vaccine against group B disease.

Citing Articles

Impact of Vaccines; Health, Economic and Social Perspectives.

Rodrigues C, Plotkin S Front Microbiol. 2020; 11:1526.

PMID: 32760367 PMC: 7371956. DOI: 10.3389/fmicb.2020.01526.

How the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective Neisseria meningitidis Vaccines.

Gasparini R, Panatto D, Bragazzi N, Lai P, Bechini A, Levi M J Immunol Res. 2015; 2015:189153.

PMID: 26351643 PMC: 4553322. DOI: 10.1155/2015/189153.

The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis?.

Maiden M Philos Trans R Soc Lond B Biol Sci. 2013; 368(1623):20120147.

PMID: 23798695 PMC: 3720045. DOI: 10.1098/rstb.2012.0147.

Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease.

McNeil L, Zagursky R, Lin S, Murphy E, Zlotnick G, Hoiseth S Microbiol Mol Biol Rev. 2013; 77(2):234-52.

PMID: 23699256 PMC: 3668674. DOI: 10.1128/MMBR.00056-12.

Neutralization of meningococcal endotoxin by antibody to core glycolipid.

Davis C, Ziegler E, Arnold K J Exp Med. 1978; 147(4):1007-17.

PMID: 418134 PMC: 2184252. DOI: 10.1084/jem.147.4.1007.

References
1.
Tramont E, Sadoff J, Artenstein M . Cross-reactivity of Neisseria gonorrhoeae and Neisseria meningitidis and the nature of antigens involved in the bactericidal reaction. J Infect Dis. 1974; 130(3):240-7. DOI: 10.1093/infdis/130.3.240. View
2.
Wahdan M, Rizk F, EL-GHOROURY A, Hablas R, Girgis N, Amer A . A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. Bull World Health Organ. 1973; 48(6):667-73. PMC: 2483073. View
3.
Wyle F, Artenstein M, Brandt B, Tramont E, Kasper D, Altieri P . Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis. 1972; 126(5):514-21. DOI: 10.1093/infdis/126.5.514. View
4.
Gotschlich E, Liu T, Artenstein M . Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. J Exp Med. 1969; 129(6):1349-65. PMC: 2138651. DOI: 10.1084/jem.129.6.1349. View
5.
Gotschlich E, Goldschneider I, Artenstein M . Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med. 1969; 129(6):1367-84. PMC: 2138657. DOI: 10.1084/jem.129.6.1367. View